Related references
Note: Only part of the references are listed.Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
Andrew S. McDaniel et al.
BJU INTERNATIONAL (2017)
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Hatem H. Soliman
ONCOTARGETS AND THERAPY (2017)
Zinc Oxide Nanoparticle-Poly I:C RNA Complexes: Implication as Therapeutics against Experimental Melanoma
Meghana Ramani et al.
MOLECULAR PHARMACEUTICS (2017)
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Tyrel T. Smith et al.
NATURE NANOTECHNOLOGY (2017)
Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine
Gao-Na Shi et al.
BIOMATERIALS (2017)
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet
Gabriele D'Errico et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Functional characterization of recombinant human granulocyte colony stimulating factor (hGMCSF) immobilized onto silica nanoparticles
Selvarajan Vanitha et al.
BIOTECHNOLOGY LETTERS (2016)
Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution
Nikolas H. Stoecklein et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Configuration-dependent Presentation of Multivalent IL-15: IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity
Enping Hong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Recent advances in nanotechnology-based detection and separation of circulating tumor cells
Ja Hye Myung et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2016)
Interleukin-2 Functionalized Nanocapsules for T Cell-Based lmmunotherapy
Stefanie U. Frick et al.
ACS NANO (2016)
One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy
Yu Zhang et al.
ADVANCED MATERIALS (2016)
Personalized approaches to active immunotherapy in cancer
Eran Ophir et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation
Ce Wang et al.
BIOMATERIALS (2016)
Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
Xiao Zhao et al.
BIOMATERIALS (2016)
Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach
Yao Lu et al.
CANCER LETTERS (2016)
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
Christian F. Jehn et al.
CLINICAL BREAST CANCER (2016)
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
Frank C. Passero et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies
Joana Mograo et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2016)
A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
Shota Warashina et al.
JOURNAL OF CONTROLLED RELEASE (2016)
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
F. Danhier
JOURNAL OF CONTROLLED RELEASE (2016)
Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens
Soodabeh Iranpour et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Clinical and biological significance of circulating tumor cells in cancer
Takaaki Masuda et al.
MOLECULAR ONCOLOGY (2016)
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Chao Wang et al.
NANO LETTERS (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias
Nirali N. Shah et al.
PEDIATRIC BLOOD & CANCER (2016)
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Daniel Bobo et al.
PHARMACEUTICAL RESEARCH (2016)
Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy
Alberto Purwada et al.
ADVANCED HEALTHCARE MATERIALS (2016)
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy
Karlo Perica et al.
ACS NANO (2015)
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer
E. M. Dijkgraaf et al.
ANNALS OF ONCOLOGY (2015)
Linking form to function: Biophysical aspects of artificial antigen presenting cell design
Karlo Perica et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2015)
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
Rodney A. Rosalia et al.
BIOMATERIALS (2015)
Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer
Sean G. Smith et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Induction of Potent Adaptive Immunity by the Novel Polyion Complex Nanoparticles
Tomofumi Uto et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer
Hannah A. Blair et al.
DRUGS (2015)
Nab-paclitaxel in patients with metastatic melanoma
Roberto A. Leon-Ferre et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy
Min Beom Heo et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
Connie P. M. Duong et al.
MOLECULAR IMMUNOLOGY (2015)
Nanotechnology for enrichment and detection of circulating tumor cells
Saheel Bhana et al.
NANOMEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Concise Review: Humanized Models of Tumor Immunology in the 21st Century: Convergence of Cancer Research and Tissue Engineering
Boris Michael Holzapfel et al.
STEM CELLS (2015)
Assessment of the enhancement of PLGA nanoparticle uptake by dendritic cells through the addition of natural receptor ligands and monoclonal antibody
Adam A. Walters et al.
VACCINE (2015)
In vivo capture and label-free detection of early metastatic cells
Samira M. Azarin et al.
NATURE COMMUNICATIONS (2015)
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Neil L. Berinstein et al.
ONCOIMMUNOLOGY (2015)
Enhancement of MHC-I Antigen Presentation via Architectural Control of pH-Responsive, Endosomolytic Polymer Nanoparticles
John T. Wilson et al.
AAPS JOURNAL (2015)
Discontinued in 2013: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
Tiansuo Zhao et al.
ONCOTARGET (2015)
Emerging Role of Nanomaterials in Circulating Tumor Cell Isolation and Analysis
Hyeun Joong Yoon et al.
ACS NANO (2014)
Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis
Ram Eitan et al.
ANTI-CANCER DRUGS (2014)
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
Joachim Rom et al.
ANTI-CANCER DRUGS (2014)
T cell antigen receptor activation and actin cytoskeleton remodeling
Sudha Kumari et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2014)
Particle shape dependence of CD8+T cell activation by artificial antigen presenting cells
Joel C. Sunshine et al.
BIOMATERIALS (2014)
Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response
Susan N. Thomas et al.
BIOMATERIALS (2014)
Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer iMmunotherapy
Yuta Yoshizaki et al.
BIOMATERIALS (2014)
The effect of combined IL10 siRNA and CpG ODN as pathogenmimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
Pallab Pradhan et al.
BIOMATERIALS (2014)
Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies
Qianjun Zhou et al.
CANCER LETTERS (2014)
Bioengineered Implantable Scaffolds as a Tool to Study Stromal-Derived Factors in Metastatic Cancer Models
Francesca Bersani et al.
CANCER RESEARCH (2014)
Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy
Lawrence D. Kaplan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
Ignace Vergote et al.
GYNECOLOGIC ONCOLOGY (2014)
Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study
Luis J. Cruz et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses
Salka Keller et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15-Dependent DC Crosstalk
Kartik Sehgal et al.
JOURNAL OF IMMUNOLOGY (2014)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Nanoscale artificial antigen presenting cells for T cell immunotherapy
Karlo Perica et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma
Anas Alrwas et al.
MELANOMA RESEARCH (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides
John T. Wilson et al.
ACS NANO (2013)
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant
Annina M. Hafner et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy
Eiji Yuba et al.
BIOMATERIALS (2013)
A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy
Eiji Yuba et al.
BIOMATERIALS (2013)
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
Jeffrey A. Silverman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Localized Immunotherapy via Liposome-Anchored Anti-CD137+IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity
Brandon Kwong et al.
CANCER RESEARCH (2013)
A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
Cheryl Lai-Lai Chiang et al.
CLINICAL CANCER RESEARCH (2013)
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Michal J. Besser et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies
Laura E. Ruff et al.
INTEGRATIVE BIOLOGY (2013)
Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model
Aniruddha Roy et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes
Yiran Zheng et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Nanogel vaccines targeting dendritic cells: Contributions of the surface decoration and vaccine cargo on cell targeting and activation
L. J. Thomann-Harwood et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
Lana E. Kandalaft et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients
Johannes C. Fischer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
Alexandre de Titta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study
Fiona Simpkins et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles
Matthias T. Stephan et al.
BIOMATERIALS (2012)
Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN
Luis J. Cruz et al.
BIOMATERIALS (2012)
Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice
Marc Mueller et al.
JOURNAL OF CONTROLLED RELEASE (2012)
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
Neil L. Berinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Jason Park et al.
NATURE MATERIALS (2012)
Anticancer and Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative of LPS for Combined Chemo-immunotherapy
Aniruddha Roy et al.
PHARMACEUTICAL RESEARCH (2012)
Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA Nanoparticles
Shashi Prasad et al.
PHARMACEUTICAL RESEARCH (2012)
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses
Rachel A. Gottschalk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Circulating tumor cells: the substrate of personalized medicine?`
Bryan T. Greene et al.
FRONTIERS IN ONCOLOGY (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles
Gizem Tincer et al.
BIOMATERIALS (2011)
The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway
Tomofumi Uto et al.
BIOMATERIALS (2011)
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery
Zhiping Zhang et al.
BIOMATERIALS (2011)
Enrichment of Circulating Tumor Cells from a Large Blood Volume Using Leukapheresis and Elutriation: Proof of Concept
Robert L. Eifler et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
Andrew J. Armstrong et al.
MOLECULAR CANCER RESEARCH (2011)
Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle
Hong Yao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy
Shashi Prasad et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
Cheryl Lai-Lai Chiang et al.
PLOS ONE (2011)
Nanoparticle Delivery Systems in Cancer Vaccines
Yogita Krishnamachari et al.
PHARMACEUTICAL RESEARCH (2011)
Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles
Samar Hamdy et al.
PHARMACEUTICAL RESEARCH (2011)
In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles
Christopher M. Jewell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer
Michael S. Sabel et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade
Lana E. Kandalaft et al.
GYNECOLOGIC ONCOLOGY (2010)
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
Fabienne Danhier et al.
JOURNAL OF CONTROLLED RELEASE (2010)
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
Rachel A. Gottschalk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy
Somayeh Hallaj-Nezhadi et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2010)
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles
Matthias T. Stephan et al.
NATURE MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Circulating tumour cells: their utility in cancer management and predicting outcomes
Matthew G. Krebs et al.
Therapeutic Advances in Medical Oncology (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy
Yuki Hor et al.
BIOMATERIALS (2009)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Laura A. Johnson et al.
BLOOD (2009)
Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
R. C. F. Leonard et al.
BREAST (2009)
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
Marta Pestrin et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12
David A. Zaharoff et al.
CANCER RESEARCH (2009)
Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
Geoffrey W. Stone et al.
PLOS ONE (2009)
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
E. Jonasch et al.
BRITISH JOURNAL OF CANCER (2008)
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel
Shinichi Kageyama et al.
CANCER SCIENCE (2008)
Nanoparticles target distinct dendritic cell populations according to their size
Vania Manolova et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells
Erin R. Steenblock et al.
MOLECULAR THERAPY (2008)
Micropatterning of costimulatory ligands enhances CD4+ T cell function
Keyue Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity
Samar Hamdy et al.
VACCINE (2008)
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid
Weihsu Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Interleukin-12: Biological properties and clinical application
Michele Del Vecchio et al.
CLINICAL CANCER RESEARCH (2007)
L-BLP25: A peptide vaccine strategy in non-small cell lung cancer
Randeep Sangha et al.
CLINICAL CANCER RESEARCH (2007)
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm et al.
BREAST CANCER RESEARCH (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
S. Lowis et al.
BRITISH JOURNAL OF CANCER (2006)
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy
S. A. North et al.
JOURNAL OF UROLOGY (2006)
Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes
Karen Zaks et al.
JOURNAL OF IMMUNOLOGY (2006)
Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer
HS Kim et al.
IMMUNOLOGY LETTERS (2006)
Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells
R Mahdian et al.
MEDICAL ONCOLOGY (2006)
Metastasis: a question of life or death
P Mehlen et al.
NATURE REVIEWS CANCER (2006)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
CA Uyl-de Groot et al.
VACCINE (2005)
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development
LR Kelland
EUROPEAN JOURNAL OF CANCER (2004)
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
JS Yu et al.
CANCER RESEARCH (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer
CE Swenson et al.
ANTI-CANCER DRUGS (2003)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
